Core Points - The company, Shanghai First Pharmaceutical Co., Ltd., has reported its third-quarter operational data for 2025, ensuring the accuracy and completeness of the information provided [8]. Financial Data - The financial statements for the third quarter are unaudited, and the report covers the period from the beginning to the end of the quarter [3][7]. - The company has not recognized any non-recurring gains or losses during the reporting period [4]. Store Operations - As of September 30, 2025, the company operates 214 stores, including 48 franchise stores, with a total operating area of 21,768.9 square meters [8]. - In the first nine months of 2025, the company added 6 new stores, with a total of 22 new openings (9 direct-operated and 13 franchise), while closing 16 stores [8]. - Among the 166 direct-operated stores, 129 have obtained the qualification as "medical insurance designated retail pharmacies," representing 77.71% of the total direct-operated stores, an increase of 10.05 percentage points compared to the end of the previous year [8].

Core Insights - The company reported a revenue of 542,480,778.50 yuan for the third quarter of 2025, representing a year-on-year growth of 14.04% [1] - The net profit attributable to shareholders of the listed company was 39,245,693.69 yuan, showing a significant year-on-year increase of 123.80% [1]

证券代码：600833 证券简称：第一医药 公告编号：临 2025-048 上海第一医药股份有限公司 一、报告期门店变动情况 2025 年第三季度经营数据公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 上海第一医药股份有限公司（以下简称"公司"）根据《上海证券交易所上市公司自 律监管指引第 3 号——行业信息披露（第四号——零售）》的相关要求，现将公司 2025 年第三季度主要经营数据披露如下： 二、报告期末主要经营数据 | 分地区 | 营业收入（元） | 营业收入比 同期增减(%) | 营业成本（元） | 营业成本比 同期增减(%) | 毛利率 (%) | 毛利率比同期增减 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 上海 地区 | 1,498,084,623.02 | 12.47 | 1,283,908,641.61 | 13.14 | 14.30 | 减少 0.51 | 个百分点 | 特此公告。 上海第一医药股份有限公司董事会 2025 年 10 ...

Financial Performance - The company's operating revenue for Q3 2025 was ¥542,480,778.50, representing a year-on-year increase of 14.04%[3] - The total profit for the quarter was ¥52,374,952.68, a significant increase of 124.02% compared to the same period last year[3] - Net profit attributable to shareholders was ¥39,245,693.69, up 123.80% year-on-year[3] - The basic earnings per share for the quarter was ¥0.1759, reflecting a 123.79% increase compared to the previous year[3] - The net profit attributable to shareholders for the year-to-date was ¥53,269,885.92, down 63.84% compared to the previous year[3] - The net profit for the first three quarters of 2025 is CNY 54,020,386.58, a decrease from CNY 147,358,092.70 in the same period of 2024, representing a decline of approximately 63.4%[18] - Operating profit for the first three quarters of 2025 is CNY 63,455,424.94, down from CNY 153,647,524.75 in 2024, indicating a decrease of about 58.7%[18] - The total comprehensive income for the first three quarters of 2025 is CNY 74,974,927.96, down from CNY 146,660,041.96 in 2024, a decrease of approximately 48.9%[18] - Basic and diluted earnings per share for the first three quarters of 2025 are both CNY 0.2388, down from CNY 0.6604 in 2024, representing a decline of about 63.8%[18] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,030,693,993.01, an increase of 2.56% from the end of the previous year[4] - Total assets as of September 30, 2025, amounted to CNY 2,030,693,993.01, up from CNY 1,980,057,333.84 at the end of 2024, an increase of 2.5%[14] - Total liabilities increased slightly to CNY 860,399,830.63 from CNY 835,659,103.08, reflecting a growth of 2.9%[13] - Shareholders' equity rose to CNY 1,170,294,162.38, compared to CNY 1,144,398,230.76 in 2024, an increase of 2.3%[14] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥24,541,621.52[3] - Cash flow from operating activities for the first three quarters of 2025 is CNY 24,541,621.52, compared to a negative cash flow of CNY 51,595,472.56 in the same period of 2024, showing a significant improvement[20] - The cash flow from investing activities for the first three quarters of 2025 is CNY 6,852,987.70, compared to CNY 4,793,074.33 in 2024, reflecting an increase of approximately 43.0%[21] - The total cash outflow from financing activities for the first three quarters of 2025 is CNY 190,377,229.39, compared to CNY 218,473,721.73 in 2024, indicating a decrease of approximately 12.9%[21] - The cash and cash equivalents at the end of the period for 2025 is CNY 368,615,925.25, up from CNY 277,907,854.36 in 2024, indicating a growth of about 32.6%[21] Operational Metrics - Total operating revenue for the first three quarters of 2025 reached CNY 1,539,077,117.96, an increase of 12.4% compared to CNY 1,368,880,300.43 in the same period of 2024[17] - Total operating costs for the first three quarters of 2025 were CNY 1,536,044,900.73, up from CNY 1,367,296,395.88 in 2024, reflecting a growth of 12.4%[17] - Operating profit margin improved, with operating costs as a percentage of revenue decreasing from 100.1% in 2024 to 99.9% in 2025[17] - The company reported a net profit for the first three quarters of 2025, with a profit margin improvement due to cost management strategies implemented during the period[17] Inventory and Receivables - Inventory increased significantly to CNY 406,629,703.58, compared to CNY 336,323,956.50 in 2024, marking a rise of 20.9%[12] - Accounts receivable decreased to CNY 172,162,204.84 from CNY 189,373,266.78, a reduction of 9.4%[11] Other Information - The company received compensation for property expropriation, which significantly impacted the profit figures for the quarter[5] - The weighted average return on equity decreased by 9.25 percentage points to 4.64% year-to-date[3] - The company reported non-recurring gains and losses totaling ¥38,619,257.70 for the quarter[6] - The company has not executed any mergers or acquisitions during the reporting period[22]

Market Overview - The pharmaceutical commercial sector increased by 0.44% on October 23, with Jianfa Zhixin leading the gains [1] - The Shanghai Composite Index closed at 3922.41, up 0.22%, while the Shenzhen Component Index closed at 13025.45, also up 0.22% [1] Stock Performance - Jianfa Zhixin (301584) saw a significant rise of 20.00%, closing at 37.20 with a trading volume of 301,100 shares and a transaction value of 1.046 billion [1] - Other notable performers included: - Kaikai Industrial (600272) up 2.20% to 13.49 [1] - First Pharmaceutical (600833) up 1.97% to 14.01 [1] - Dazhenlin (603233) up 1.48% to 19.20 [1] - Yifeng Pharmacy (603939) up 1.31% to 25.44 [1] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 97.0483 million from institutional investors and 117 million from speculative funds, while retail investors saw a net inflow of 214 million [2] - The capital flow for key stocks showed: - Jianfa Zhixin had a net inflow of 1.22 billion from institutional investors, but a net outflow of 58.2871 million from speculative funds [3] - Kaikai Industrial had a net inflow of 15.4487 million from institutional investors, with a net outflow of 3.9622 million from speculative funds [3]

Core Insights - The pharmaceutical commercial sector saw an increase of 0.83% on October 22, with Jianfa Zhixin leading the gains [1] - The Shanghai Composite Index closed at 3913.76, down 0.07%, while the Shenzhen Component Index closed at 12996.61, down 0.62% [1] Stock Performance - Jianfa Zhixin (301584) closed at 31.00, up 7.19% with a trading volume of 238,100 shares and a transaction value of 734 million [1] - Guoyao Shares (600511) closed at 29.89, up 3.75% with a trading volume of 180,500 shares and a transaction value of 539 million [1] - Zhejiang Nongyuan (000705) closed at 9.81, up 3.05% with a trading volume of 117,170 shares and a transaction value of 168 million [1] - Other notable stocks include Jiashitang (002462) up 1.51%, Daclin (603233) up 1.34%, and Guofa Shares (600538) up 1.20% [1] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 98.42 million from institutional investors and 51.45 million from retail investors, while individual investors saw a net inflow of 150 million [2] - The capital flow for key stocks shows varying trends, with Shanghai Pharmaceuticals (601607) seeing a net inflow of 31.94 million from institutional investors [3] - Jianfa Zhixin (301584) had a net inflow of 18.64 million from institutional investors but a net outflow of 2.07 million from retail investors [3]

Market Overview - The pharmaceutical commercial sector increased by 0.55% on October 21, with First Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3916.33, up 1.36%, while the Shenzhen Component Index closed at 13077.32, up 2.06% [1] Stock Performance - First Pharmaceutical (600833) closed at 13.64, up 2.48% with a trading volume of 58,500 shares and a transaction value of 79.03 million yuan [1] - Other notable performers included: - Haiwang Biological (000078) at 2.55, up 2.41% [1] - HeFu China (603122) at 6.55, up 2.34% [1] - Ruikang Pharmaceutical (002589) at 2.93, up 2.09% [1] - Daclin (603233) at 18.67, up 1.52% with a transaction value of 293 million yuan [1] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 105 million yuan from institutional investors and 110 million yuan from speculative funds, while retail investors saw a net inflow of 215 million yuan [2] - The capital flow for individual stocks showed mixed results, with China Pharmaceutical (600056) seeing a net inflow of 28.32 million yuan from institutional investors [3] Individual Stock Capital Flow - Key stocks with significant capital flow include: - China Pharmaceutical (600056) with a net inflow of 28.32 million yuan from institutional investors [3] - Jiuzhoutong (600998) with a net inflow of 24.77 million yuan from institutional investors [3] - Shanghai Pharmaceutical (601607) with a net inflow of 11.37 million yuan from institutional investors [3]

Group 1 - The company, Shanghai First Pharmaceutical Co., Ltd., plans to sign a compensation agreement for the expropriation of eight properties used for storage and rental purposes by its wholly-owned subsidiary, First Pharmaceutical Chain Co., Ltd. [2][4] - The total compensation amount for the expropriated properties is approximately 32.78 million yuan, to be paid within 90 days after the agreement takes effect and the properties are vacated [3][5] - The compensation agreement has been approved by the company's board of directors and will not constitute a related party transaction or a major asset restructuring as per relevant regulations [6][7] Group 2 - The expropriated properties are located at Beijing East Road, and their primary use is for the company's operations, which will not significantly impact the business [7] - The compensation will be recorded in the company's financial statements and is expected to have a positive effect on the annual operating performance, subject to audit confirmation [7][8] - The company will closely monitor the progress of the compensation agreement and fulfill its disclosure obligations as required by law [9]

上海第一医药股份有限公司 关于全资子公司拟签订房屋征收补偿协议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责 任。 一、本次交易概述 根据上海市黄浦区人民政府《上海市黄浦区人民政府房屋征收决定》（黄府征【2024】 4 号），位于上海市黄浦区北京东路 360 弄 12 号底层客堂房屋、5 号底后厢房屋、7 号 底东后厢房屋、5.7 号底层客堂房屋、7 号底西后厢房屋、5 号底层中厢房屋、5 号底层 东前厢房屋、5 号底客天井房屋的 8 处相邻房屋被纳入黄浦区 149、151 街坊旧城区改建 房屋征收范围。上述八处房屋系公司全资子公司第一医药商店连锁经营有限公司（以下 简称"一医连锁"）向上海新黄浦（集团）有限责任公司承租的公有非居住房屋，主要 用于自用仓储，部分用于对外出租经营使用。 本次房屋征收单位为"上海市黄浦区住房保障和房屋管理局"，房屋征收实施单位 为"上海市黄浦第五房屋征收服务事务所有限公司"，房屋评估单位为"上海百盛房地 产估价有限责任公司"。 经多次协商，目前已就征收补偿事宜基本达成一致，一医连锁拟与房屋征收 ...

Core Viewpoint - The company, First Pharmaceutical (600833.SH), is undergoing a property acquisition process as part of a government-led urban redevelopment initiative in Shanghai's Huangpu District, which involves the compensation for eight properties used for storage and rental purposes [1][2]. Group 1: Property Acquisition Details - The properties involved in the acquisition are located at 360 Lane 12, Beijing East Road, Huangpu District, and include eight adjacent non-residential buildings [1]. - The properties are leased by the company's wholly-owned subsidiary, First Pharmaceutical Chain Co., Ltd., primarily for self-storage and partially for external rental operations [1]. Group 2: Compensation Agreement - According to the compensation agreement, First Pharmaceutical Chain is set to receive a total compensation of 32.776 million yuan for the eight properties [2]. - The payment is scheduled to be made within 90 days following the agreement's effectiveness, relocation, and signing of the settlement document [2].